CBS - The 17th Left Main & Coronary Bifurcation Summit, CBS2025

CBS 2019

CBSMD教育中心

HOME
CBS 2019
At CBS

General Information

Left Main & Coronary Bifurcation Summit (CBS) was founded in 2006 as a think tank dedicated to the treatment of left main and coronary bifurcation lesions. CBS aims to improve cardiological care by refreshing fundamental researches, clinical trials, yearly published guidelines, emerged ideas and case-based discussion.

Association and Affiliations
- Organized by
  
  Nanjing Heart Center
  
  Asian Bifurcation Club (ABC)
  
  Nanjing First Hospital, Nanjing Medical University
- Co-organized by
  
  Chinese Society of Cardiology (CSC)
  
  Capacity Building and Continuing Education Center,National Health and Family Planning Commission (CBCEC)
  
  American Society for Cardiovascular Angiography and Interventions (SCAI)
  
  Asian Heart Society (AHS)
Contact Us
- Registration Administration of Domestic Representatives
  
  Hongjuan Peng : +86-13913895477
  
  Haimei Xu +86-13914736846
  
  cbsnj@cbsmd.cn
- Registration Administration of Overseas Representatives
  
  Ling Lin : +86 (25) 52271398
  
  +86-13951884596
  
  cbs@cbsmd.cn
- Management of Challenging Cases
  
  Yingying Zhao :+86-13815408517
  
  sub@cbsmd.cn
Address

CBS2019 Congress Secretariat, Nanjing First Hospital, Building No.9 68# Changle Road, Nanjing, China

210006
FACULTY
FACULTY

General Chairman
Congress Chairman
Course Directors International Faculty Domestic Faculty Hong Kong and Taiwan Faculty Members of Academic Committee
Education Center

Education Center

• Online Education (For more customized user interface with self-defined collection of research papers and education resources.)

• CBS Education Resource

• CBSMD Scientific Library
SCIENTIFIC LIBRARY

SCIENTIFIC LIBRARY

Research Paper

> Acute Coronary Syndrom

> ASCVD Prevention

> Bifurcation Stenting

> Cardio-Oncology

> Congestive Heart Failure

> DAPT Duration

> Drug Coated Balloon

> Fractional Flow Reserve

> IVUS Guidance

> Optical Coherence Tomography

> Pulmonary Hypertension

> Rotational Atherectomy

> Shear Stress

> Stenting Left Main

> Transcatheter Aortic Valve Replacement

> Percutaneous LAA Occlusion

> Mitral/Tricuspid Valvular Disease

> Other Relevant Articles

Recommended Paper

Management of Acute Myocardial Infarction During the COVID-19 Pandemic

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19)

< >

HOME | SCIENTIFIC LIBRARY | 血流储备分数

血流储备分数

Cutoff Value and Long-Term Prediction of Clinical Events by FFR Measured Immediately After Implantation of a Drug-Eluting Stent in Patients With Coronary Artery Disease: 1- to 3-Year Results From the DKCRUSH VII Registry Study Clinical value of post-percutaneous coronary intervention fractional flow reserve value: A systematic review and meta-analysis Diagnostic performance of noninvasive fractional flow reserve derived from coronary computed tomography angiography in suspected coronary artery disease: the NXT trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps) Prognostic Value of Fractional Flow Reserve Measured Immediately After Drug-Eluting Stent Implantation Anatomical plaque and vessel characteristics are associated with hemodynamic indices including fractional flow reserve and coronary flow reserve: A prospective exploratory intravascular ultrasound analysis Prognostic Implication of Thermodilution Coronary Flow Reserve in Patients Undergoing Fractional Flow Reserve Measurement Clinical Significance of Concordance or Discordance Between Fractional Flow Reserve and Coronary Flow Reserve for Coronary Physiological Indices, Microvascular Resistance, and Prognosis After Elective Percutaneous Coronary Intervention Correlation between frequency-domain optical coherence tomography and fractional flow reserve in angiographically-intermediate coronary lesions

Sort by hits |<< 1 2 3 4 5 6 7 8 9 >>|

Original Research

JOURNAL：CBSMD Article Link

药物涂层球囊在小血管介入中的应用

CBSMD

Pre-reading

DCB经现阶段临床试验证实在冠脉小血管狭窄干预方向与DES可一决高下，其优势在于：

1) 不改变血管解剖结构；

2) 药物涂层球囊具抗血管壁增生药物，可起到预防支架内再狭窄之目的；

3) 有证据提示DCB术后DAPT服药周期可短于DES术后；

4) DCB可为后续CABG或支架置入赢取更多可能。

将DCB应用在小血管介入领域时应持有的谨慎态度：

1）尽管现有指南尚未对DCB应用前腔内影像学IVUS，OCT的仔细评估做明确规定，但已有证据显示腔内影像学的先进性在指导DES置入或DCB时可转换为更好的预后；

2）应进一步明确DCB适应证及人群。

围绕DCB术后预后非劣效于DES预后的RCT研究包括：

2018年8月“Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial”

样本：欧洲14个介入中心758例，随机比DES (paclitaxel-eluting stent) vs. DCB 1:1

病变：<3 mm直径的冠脉病变

随访：1年

DAPT：DCB组4周，DES组non-ACS患者 6周，ACS患者1年

结论: 在一年内，所有小血管疾病(< 3mm)患者随机分配到DES组和DCB组，组间MACE一年发生率无差异，符合非劣效性标准。

2018年12月“Drug-Coated Balloon Versus Drug-Eluting Stent for Small-Vessel Disease: The RESTORE SVD China Randomized Trial”

样本：多中心230例

病变：2.25 ≤冠脉小血管直径 ≤2.75 mm

随访：9个月和1年

结论：9个月造影随访DCB组节段狭窄直径百分比较DES组下降了10.9%，满足非劣效标准；而一年组间靶病变失败率无统计学差异。

2019年5月“Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction: The REVELATION Randomized Trial”

样本：单中心120例

病变：STEMI, 罪犯病变非严重钙化，预扩后残余冠脉狭窄 <50%

随访：9个月FFR随访

结论：STEMI经PPCI-DCB策略干预后，其FFR评估结果非劣效于DES策略。

更多内容详细参阅“Drug-Coated Balloon-Only Percutaneous Coronary Intervention for the Treatment of De Novo Coronary Artery Disease: A Systematic Review”和《紫杉醇涂层球囊的最新研究进展》。

>CBS

CBS 2019

> CBS 2019 REGISTRATION

> CBS 2019 PROGRAM

> CBS 2019 CALL FOR SCIENCE

> CBS 2019 SPOTLIGHTS

CBSMD

> CBSMD WEBSITE REGISTRATION

> EDUCATION CENTER

> RECOMMANDED PAPER

> TOP 10 RESEARCH PAPER

CBS 2019

CBS 2019 FACULTY

Education Resource

CBSMD Scientific Library